Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis
-
Adriana F. Neves
,
Jaqueline D. Dores Dias-Oliveira
Abstract
Background: The non-coding prostate cancer antigen 3 (PCA3) RNA is currently the most specific biomarker for prostate cancer (PCa) diagnosis. Although its clinical value has been validated in a urine assay after intensive prostatic massage, few studies have been conducted to establish its diagnostic value in the peripheral blood (PBL). The aim of the present study was to examine the PCA3 expression in blood as a diagnostic tool, and to provide an additional strategy to improve PCa diagnosis.
Methods: PCA3 transcripts were detected by RT-PCR in PBL and prostatic tissues from patients. PBL sampling also included a group of young healthy volunteers. The relationship between the PCA3 RNA detection and clinical characteristics was analyzed.
Results: PCA3 detection in blood presented 94% specificity and 32% sensitivity, and its combined detection in tissues significantly improved diagnostic parameters. However, PCA3 RNA detection in blood was also associated with PSA levels ≥10 ng/mL, and their combination provided a sensitivity of 60% and specificity of 93%.
Conclusions: Detection of the PCA3 RNA in patients’ blood is an efficient tool for PCa diagnosis because it allows a routine collection procedure, which is also supported by the ongoing screening marker, prostate-specific antigen (PSA). We propose its combined use with PSA levels ≥10 ng/mL, which improves accuracy, and prevents overdiagnosis and overtreatment.
The authors would like to thank the Urology Division of the University Hospital of Uberlandia for providing the biological samples, especially to the urologist Danielo Garcia de Freitas, and the pathologist Tania M. Alcântara. We would also like to thank BioGenetics Molecular Technologies Ltda, CAPES, CNPq, FAPEMIG, and FAPEG for their financial support.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Financial support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics CA cancer. J Clin 2011;61:69–90.10.3322/caac.20107Search in Google Scholar
2. Buhmeida A, Pyrhönen S, Laato M, CollanY. Prognostic factors in prostate cancer. Diagn Pathol 2006;1:4.10.1186/1746-1596-1-4Search in Google Scholar PubMed
3. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer – the post PSA era. Anticancer Res 2009;29:3289–98.Search in Google Scholar PubMed
4. Strittmatter F, Stieber P, Nagel D, Füllhase C, Walther S, Stief CG, et al. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio – is there any advantage? Eur J Med Res 2011;16:445–50.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000296748400004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1186/2047-783X-16-10-445Search in Google Scholar PubMed
5. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762–71.10.7326/0003-4819-155-11-201112060-00375Search in Google Scholar PubMed
6. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011. Epub ahead of print 19 May 2011. DOI:10.1016/j.urolonc.2011.04.001.10.1016/j.urolonc.2011.04.001Search in Google Scholar
7. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975–9.Search in Google Scholar PubMed
8. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003;62:34–43.10.1016/S0090-4295(03)00759-3Search in Google Scholar
9. Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62: 2695–8.Search in Google Scholar PubMed
10. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8–15.10.1016/S0302-2838(03)00201-XSearch in Google Scholar PubMed
11. Hessels D, van Gils MP, van Hooij O, Sander A, Jannink SA, Witjes JA, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70:10–6.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000273471800002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1002/pros.21032Search in Google Scholar PubMed
12. Fontenete S, Silva J, Teixeira AL, Ribeiro R, Bastos E, Pina F, et al. Controversies in using urine samples for prostate cancer detection: PSA and PCA3 expression analysis. Int Braz J Urol 2011;37:719–26.10.1590/S1677-55382011000600006Search in Google Scholar PubMed
13. Oliveira JD, Goulart LR, Waldesse PO, Meola J, Neves AF. DD3 gene expression in peripheral blood of patients with prostate cancer and with benign prostate hyperplasia as a molecular diagnostic. Eur Urol 2003;2(Suppl):S102.10.1016/S1569-9056(03)90463-5Search in Google Scholar
14. Väänänen RM, Rissanen M, Kauko O, Junnila S, Väisänen V, Nurmi J, et al. Quantitative real-time RT-PCR assay for PCA3. Clin Biochem 2008;41:103–8.10.1016/j.clinbiochem.2007.10.009Search in Google Scholar PubMed
15. Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M, et al. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer 2010;9:174.10.1186/1476-4598-9-174Search in Google Scholar PubMed
16. Llanes L, Ferruelo A, Páez A, Gómez JM, Moreno A, Berenguer A. The clinical utility of the prostate specific membrane antigen reverse-transcription/polymerase chain reaction to detect circulating prostate cells: an analysis in healthy men and women. Br J Urol Int 2002;89:882–5.10.1046/j.1464-410X.2002.02774.xSearch in Google Scholar
17. Martínez-Piñeiro L, Rios E, Martínez-Gomariz M, Pastor T, de Cabo M, Picazo ML, et al. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur Urol 2003;43:342–50.10.1016/S0302-2838(03)00055-1Search in Google Scholar
18. Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, et al. Prognostic value of combined “triple”-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 2004;10:5808–14.10.1158/1078-0432.CCR-1004-03Search in Google Scholar
19. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 2004;21:495–505.10.1007/s10585-004-3217-0Search in Google Scholar
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 1987;62:156–9.10.1016/0003-2697(87)90021-2Search in Google Scholar
21. Tao Z, Shen M, Zheng Y, Mao X, Chen Z, Yin Y, et al. PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. Exp Mol Pathol 2010;89:58–62.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000280019700008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.yexmp.2010.01.008Search in Google Scholar PubMed
22. Neves AF, Araújo TG, Biase WK, Meola J, Alcântara TM, Freitas DG, et al. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 2008;41:1191–8.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000260486900012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.clinbiochem.2008.06.013Search in Google Scholar PubMed
23. George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 2007;13:3507–17.10.1158/1078-0432.CCR-06-3023Search in Google Scholar PubMed PubMed Central
24. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20:22–45.10.1210/er.20.1.22Search in Google Scholar
©2013 by Walter de Gruyter Berlin Boston
Articles in the same Issue
- Letters to the Editor
- Missing agreement between the two IMMULITE® PSA assays
- “Cerebrovascular stressing”: dipyridamole-induced S100B elevation predicts ischemic cerebrovascular events
- Discrepancy in lamellar body counts (LBCs) between the Sysmex XE-2100 and Sysmex XT-2000i instruments
- Interphase fluorescent in situ hybridization detection of the 7q11.23 chromosomal inversion in a clinical laboratory: automated versus manual scoring
- Adrenocorticotropic hormone stability in preanalytical phase depends on temperature and proteolytic enzyme inhibitor
- The impact on costs and efficiency of reducing the number of collected tubes
- Improved software on the Sysmex XE-5000 BF mode for counting leukocytes in cerebrospinal fluid
- First trimester placental growth factor and soluble fms-like tyrosine kinase 1 are significantly related to PAPP-A levels
- Preliminary evaluation of complete blood cell count on Mindray BC-6800
- Rational use of laboratory tests: albuminuria
- Masthead
- Masthead
- Editorials
- Fifty years of CCLM – invitation to join us for a reception in Milan
- Personalized (laboratory) medicine: a bridge to the future
- PSA, PCA3 and the phi losophy of prostate cancer management
- Reviews
- Gender medicine: a task for the third millennium
- Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis
- Harmonization in laboratory medicine: the complete picture
- Opinion Papers
- Glycemic control in the clinical management of diabetic patients
- Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example
- Guidelines and Recommendations
- A position paper of the EFLM Committee on Education and Training and Working Group on Distance Education Programmes/E-Learning: developing an e-learning platform for the education of stakeholders in laboratory medicine
- General Clinical Chemistry and Laboratory Medicine
- A novel weighted cumulative delta-check method for highly sensitive detection of specimen mix-up in the clinical laboratory
- Identification and quantification of hemoglobins in whole blood: the analytical and organizational aspects of Capillarys 2 Flex Piercing compared with agarose electrophoresis and HPLC methods
- Determination of the fatty acid profile of neutral lipids, free fatty acids and phospholipids in human plasma
- Urinary iodine concentrations of pregnant women in Ukraine
- Delay in the measurement of eosin-5′-maleimide (EMA) binding does not affect the test result for the diagnosis of hereditary spherocytosis
- Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method
- Target analyte quantification by isotope dilution LC-MS/MS directly referring to internal standard concentrations – validation for serum cortisol measurement
- Reference Values and Biological Variations
- Reference values and upper reference limits for 26 trace elements in the urine of adults living in Belgium
- Biological variation and reference change values of common clinical chemistry and haematologic laboratory analytes in the elderly population
- Indirect determination of pediatric blood count reference intervals
- Cancer Diagnostics
- Suitability of quality control materials for prostate-specific antigen (PSA) measurement: inter-method variability of common tumor marker control materials
- Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis
- Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study
- Infectious Diseases
- Polymorphic mononuclear neutrophils CD64 index for diagnosis of sepsis in postoperative surgical patients and critically ill patients
- Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia
Articles in the same Issue
- Letters to the Editor
- Missing agreement between the two IMMULITE® PSA assays
- “Cerebrovascular stressing”: dipyridamole-induced S100B elevation predicts ischemic cerebrovascular events
- Discrepancy in lamellar body counts (LBCs) between the Sysmex XE-2100 and Sysmex XT-2000i instruments
- Interphase fluorescent in situ hybridization detection of the 7q11.23 chromosomal inversion in a clinical laboratory: automated versus manual scoring
- Adrenocorticotropic hormone stability in preanalytical phase depends on temperature and proteolytic enzyme inhibitor
- The impact on costs and efficiency of reducing the number of collected tubes
- Improved software on the Sysmex XE-5000 BF mode for counting leukocytes in cerebrospinal fluid
- First trimester placental growth factor and soluble fms-like tyrosine kinase 1 are significantly related to PAPP-A levels
- Preliminary evaluation of complete blood cell count on Mindray BC-6800
- Rational use of laboratory tests: albuminuria
- Masthead
- Masthead
- Editorials
- Fifty years of CCLM – invitation to join us for a reception in Milan
- Personalized (laboratory) medicine: a bridge to the future
- PSA, PCA3 and the phi losophy of prostate cancer management
- Reviews
- Gender medicine: a task for the third millennium
- Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis
- Harmonization in laboratory medicine: the complete picture
- Opinion Papers
- Glycemic control in the clinical management of diabetic patients
- Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example
- Guidelines and Recommendations
- A position paper of the EFLM Committee on Education and Training and Working Group on Distance Education Programmes/E-Learning: developing an e-learning platform for the education of stakeholders in laboratory medicine
- General Clinical Chemistry and Laboratory Medicine
- A novel weighted cumulative delta-check method for highly sensitive detection of specimen mix-up in the clinical laboratory
- Identification and quantification of hemoglobins in whole blood: the analytical and organizational aspects of Capillarys 2 Flex Piercing compared with agarose electrophoresis and HPLC methods
- Determination of the fatty acid profile of neutral lipids, free fatty acids and phospholipids in human plasma
- Urinary iodine concentrations of pregnant women in Ukraine
- Delay in the measurement of eosin-5′-maleimide (EMA) binding does not affect the test result for the diagnosis of hereditary spherocytosis
- Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method
- Target analyte quantification by isotope dilution LC-MS/MS directly referring to internal standard concentrations – validation for serum cortisol measurement
- Reference Values and Biological Variations
- Reference values and upper reference limits for 26 trace elements in the urine of adults living in Belgium
- Biological variation and reference change values of common clinical chemistry and haematologic laboratory analytes in the elderly population
- Indirect determination of pediatric blood count reference intervals
- Cancer Diagnostics
- Suitability of quality control materials for prostate-specific antigen (PSA) measurement: inter-method variability of common tumor marker control materials
- Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis
- Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study
- Infectious Diseases
- Polymorphic mononuclear neutrophils CD64 index for diagnosis of sepsis in postoperative surgical patients and critically ill patients
- Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia
